Social network
Our products - Giving new hope to patients with key therapeutic solutions
Our products - Giving new hope to patients with key therapeutic solutions

Our Products

Giving new hope to patients with key therapeutic solutions

Tools content (print, share, increase/decrease text size):


    Middle area:



    Sanofi’s mission is to create solutions for currently unmet medical needs. Sanofi employ innovative approaches to attack cancer on all fronts and provide medicines adapted to the diverse profiles of patients.


    Through its acquisitions and targeted partnerships, Sanofi is carrying out research on newly discovered aspects of cancer development, growth and progression.

    Sanofi is a key actor in the field of oncology, particularly in chemotherapy, with major products:

    • The taxoid Taxotere® (docetaxel) is a cornerstone of treatment for several types of cancer and is available in more than 100 countries.
    • The platinum-based agent Eloxatine® (oxaliplatin) is a major treatment in colorectal cancer and is available in more than 70 countries.
    • Jevtana® (cabazitaxel), resulting from 14 years of research and development, is a taxane derivative that is indicated for metastatic hormone-resistant prostate cancer previously treated with docetaxel. Jevtana is available in 80 countries.
    • Zaltrap® (aflibercept) is a recombinant fusion protein which acts as a soluble decoy receptor that binds to Vascular Endothelial Growth Factor-A (VEGF-A), VEGF-B and placental growth factor (PIGF), preventing the bound VEGF from binding to their native receptors. VEGF-A is one of the mediators contributing to angiogenesis. VEGF-B and PlGF, related growth factors in the VEGF family, may contribute to tumor angiogenesis as well. In the U.S, Zaltrap® is a registered trademark of Regeneron Pharmaceuticals, Inc. Zaltrap® is indicated in the colorectal metastatic cancer resistant to oxaliplatine treatment.
    • Thyrogen® (thyrotropin alfa) is used in the treatment or follow-up of differentiated thyroid cancer (1).

    To help patients and their loved-ones understand and manage the disease, Sanofi collaborates with numerous patient support associations worldwide through its affiliates.


    1. More information : / Our products

    Right area:

    Further information

    Research and Development


    © Sanofi 2004-2016 - All rights reserved - Update: June 19, 2015

    • Site complies with W3C WCAG 2.0 (new window, in english)